Even when research produces treatments or interventions designed for disabled populations, structural barriers often make them inaccessible in practice. For example, a new therapy might be priced so high that only affluent patients can afford it, or distributed in formats that exclude people with mobility, sensory, or cognitive differences. The very communities whose participation made the research possible are frequently locked out of its benefits. Research can reinforce broader patterns of exclusion unless access and affordability are deliberately prioritized.